Nuclear control of inflammation and fibrosis in nonalcoholic steatohepatitis: Therapeutic potential of dual peroxisome proliferator-activated receptor alpha/delta agonism

Hepatology

Volumn 58, Issue 6, 2013, Pages 1881-1884

  Quintero, Pablo ^a   Arrese, Marco ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

[2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ANTIFIBROTIC AGENT; COLLAGEN TYPE 1; GFT 505; INTERLEUKIN 1BETA; KD 3010; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 2-(2,6-DIMETHYL-4-(3-(4-(METHYLTHIO)PHENYL)-3-OXO-1-PROPENYL)PHENOXYL)-2-METHYLPROPANOIC ACID; CHALCONE DERIVATIVE; PROPIONIC ACID DERIVATIVE;

ARTICLE; CELL PROLIFERATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENTEROHEPATIC CIRCULATION; HEPATITIS; HUMAN; INSULIN SENSITIVITY; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER PROTECTION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STELLATE CELL; AGONISTS; ANIMAL; FATTY LIVER;

ANIMALS; CHALCONES; FATTY LIVER; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; PPAR ALPHA; PPAR DELTA; PROPIONATES;

EID: 84888286333     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26582     Document Type: Article

References (17)

1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012;142:1592-1609.
2. Bhala N, Jouness RI, Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr Pharm Des 2013; doi: 10.2174/1381213233940916128.
3. Charlton M. Evolving aspects of liver transplantation for nonalcoholic steatohepatitis. Curr Opin Organ Transplant 2013;18:251-258.
4. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease, or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:330-344.
5. Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, Millatt LJ, et al. Hepato-protective effects of the dual PPARα/δ agonist gft505 in rodent models of NAFLD/NASH. Hepatology 2013;58:1941-1952.
6. Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol Res 2005;51:85-94.
7. Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab 2012;23:351-363.
8. Videla LA, Pettinelli P. Misregulation of PPAR Functioning and its pathogenic consequences associated with nonalcoholic fatty liver disease in human obesity. PPAR Res 2012;2012:107434.
9. Arrese M, Karpen SJ. Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases. Clin Pharmacol Ther 2010;87:473-478.
10. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010;52:79-104.
11. Bortolini M, Wright MB, Bopst M, Balas B. Examining the safety of PPAR agonists - current trends and future prospects. Expert Opin Drug Saf 2013;12:65-79.
12. Iwaisako K, Haimerl M, Paik YH, Taura K, Kodama Y, Sirlin C, et al. Protection from liver fibrosis by a peroxisome proliferator-activated receptor delta agonist. Proc Natl Acad Sci U S A 2012;109:E1369-E1376.
13. Bojic LA, Huff MW. Peroxisome proliferator-activated receptor delta: a multifaceted metabolic player. Curr Opin Lipidol 2013;24:171-177.
14. Adeghate E, Adem A, Hasan MY, Tekes K, Kalasz H. Medicinal chemistry and actions of dual and pan PPAR modulators. Open Med Chem J 2011;5:93-98.
15. Kostadinova R, Montagner A, Gouranton E, Fleury S, Guillou H, Dombrowicz D, et al. GW501516-activated PPARbeta/delta promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation. Cell Biosci 2012;2:34.
16. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008;295:G987-G995.
17. Cariou B, Hanf R, Lambert-Porcheron S, Zair Y, Sauvinet V, Noel B, et al. Dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care 2013 (in press).